{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:12:16Z","timestamp":1793121136410,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":29,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006419","name":"EuroQol Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006419","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jval.2026.07.002","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:54:28Z","timestamp":1785426868000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Health-Related Quality of Life and Utility Values in Chinese Patients With Non-Small Cell Lung Cancer: A Multicenter Study"],"prefix":"10.1016","author":[{"given":"Luying","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingqi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejing","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongchao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongfu","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinhua","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongfei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maobai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuansheng","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifu","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruxu","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiting","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jval.2026.07.002_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.jval.2026.07.002_bib2","first-page":"47","article-title":"Cancer incidence and mortality in China, 2022","volume":"4","author":"Han","year":"2024","journal-title":"J Natl Cancer Cent"},{"key":"10.1016\/j.jval.2026.07.002_bib3","series-title":"GHDx. 2020 China Cancer Registry Annual Report","year":"2022"},{"issue":"10066","key":"10.1016\/j.jval.2026.07.002_bib4","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0140-6736(16)30958-8","article-title":"Lung cancer: current therapies and new targeted treatments","volume":"389","author":"Hirsch","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jval.2026.07.002_bib5","doi-asserted-by":"crossref","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","article-title":"Non-small cell lung cancer, version 4.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Riely","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"10.1016\/j.jval.2026.07.002_bib6","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jval.2025.10.002","article-title":"Impact of China\u2019s national drug price negotiation policy on availability, affordability, and regional equity of negotiated drugs: a multidimensional nationwide analysis, 2018 to 2021","volume":"29","author":"Qiu","year":"2026","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.jval.2026.07.002_bib7","doi-asserted-by":"crossref","first-page":"e195","DOI":"10.1111\/ajco.12477","article-title":"Health state utilities in non-small cell lung cancer: an international study","volume":"13","author":"Nafees","year":"2017","journal-title":"Asia Pac J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jval.2026.07.002_bib8","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2217\/cer-2017-0069","article-title":"Health state utilities in patients with advanced non-small-cell lung cancer in China","volume":"7","author":"Shen","year":"2018","journal-title":"J Comp Eff Res"},{"issue":"6","key":"10.1016\/j.jval.2026.07.002_bib9","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jval.2020.12.017","article-title":"Vignette-based utilities: usefulness, limitations, and methodological recommendations","volume":"24","author":"Matza","year":"2021","journal-title":"Value Health"},{"issue":"6","key":"10.1016\/j.jval.2026.07.002_bib10","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s40273-020-00893-8","article-title":"A comparison of the EQ-5D-3L and EQ-5D-5L","volume":"38","author":"Thompson","year":"2020","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"10.1016\/j.jval.2026.07.002_bib11","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.7150\/jca.11239","article-title":"Chemotherapeutic response and prognosis among lung cancer patients with and without depression","volume":"6","author":"Chen","year":"2015","journal-title":"J Cancer"},{"issue":"5","key":"10.1016\/j.jval.2026.07.002_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-023672","article-title":"Coping, mood and health-related quality of life: a cross-sectional study in Chinese patients with advanced lung cancer","volume":"9","author":"He","year":"2019","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/j.jval.2026.07.002_bib13","first-page":"2215","article-title":"Using a Chinese time trade-off approach to explore the health utility level and quality of life of cancer patients in urban China: a multicentre cross-sectional study","volume":"29","author":"Ding","year":"2021","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1016\/j.jval.2026.07.002_bib14","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jval.2016.11.016","article-title":"Estimating an EQ-5D-5L value set for China","volume":"20","author":"Luo","year":"2017","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.jval.2026.07.002_bib15","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40273-020-00997-1","article-title":"Valuation of SF-6Dv2 health states in China using time trade-off and discrete-choice experiment with a duration dimension","volume":"39","author":"Wu","year":"2021","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"10.1016\/j.jval.2026.07.002_bib16","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.jval.2026.07.002_bib17","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s11136-015-1217-y","article-title":"QLU-C10D: a health state classification system for a multi-attribute utility measure based on the EORTC QLQ-C30","volume":"25","author":"King","year":"2016","journal-title":"Qual Life Res"},{"issue":"1","key":"10.1016\/j.jval.2026.07.002_bib18","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12955-025-02394-8","article-title":"Mapping the EORTC QLQ-C30 and QLQ-LC13 to the SF-6D utility index in patients with lung cancer using machine learning and traditional regression methods","volume":"23","author":"Jiang","year":"2025","journal-title":"Health Qual Life Outcomes"},{"issue":"8","key":"10.1016\/j.jval.2026.07.002_bib19","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.jval.2023.02.007","article-title":"Health utility analysis of tepotinib in patients with non-small cell lung cancer harboring MET Exon 14 skipping","volume":"26","author":"Yang","year":"2023","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2026.07.002_bib20","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2147\/PPA.S344622","article-title":"Health-related quality of life and utility scores of lung cancer patients treated with traditional Chinese medicine in China","volume":"16","author":"Liu","year":"2022","journal-title":"Patient Prefer Adherence"},{"issue":"12","key":"10.1016\/j.jval.2026.07.002_bib24","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1007\/s11136-024-03776-z","article-title":"Chinese utility weights for the EORTC cancer-specific utility instrument QLU-C10D","volume":"33","author":"Cao","year":"2024","journal-title":"Qual Life Res"},{"issue":"4","key":"10.1016\/j.jval.2026.07.002_bib25","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1524-4733.2010.00695.x","article-title":"Analysis of health utility data when some subjects attain the upper bound of 1: are Tobit and CLAD models appropriate?","volume":"13","author":"Pullenayegum","year":"2010","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2026.07.002_bib26","author":"Fayers"},{"issue":"1","key":"10.1016\/j.jval.2026.07.002_bib27","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s10198-023-01566-x","article-title":"Comparative performance and mapping algorithms between EQ-5D-5L and SF-6Dv2 among the Chinese general population","volume":"25","author":"Xie","year":"2024","journal-title":"Eur J Health Econ"},{"issue":"7","key":"10.1016\/j.jval.2026.07.002_bib28","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.21037\/tcr.2019.10.28","article-title":"Analysis of real-word mutations of lung cancer driver genes in five regions of China","volume":"8","author":"Sun","year":"2019","journal-title":"Transl Cancer Res"},{"key":"10.1016\/j.jval.2026.07.002_bib29","doi-asserted-by":"crossref","first-page":"6033","DOI":"10.2147\/CMAR.S253789","article-title":"Changes and influential factors of chemotherapy usage for non-small cell lung cancer patients in China: a multicenter 10-year (2005-2014) retrospective study","volume":"12","author":"Xing","year":"2020","journal-title":"Cancer Manag Res"},{"issue":"5","key":"10.1016\/j.jval.2026.07.002_bib30","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1007\/s00432-020-03444-y","article-title":"Clinicopathological and molecular characteristics associated with PD-L1 expression in non-small cell lung cancer: a large-scale, multi-center, real-world study in China","volume":"147","author":"Zheng","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"issue":"10","key":"10.1016\/j.jval.2026.07.002_bib31","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/cac2.12359","article-title":"Non-small cell lung cancer in China","volume":"42","author":"Chen","year":"2022","journal-title":"Cancer Commun (Lond)"},{"issue":"1","key":"10.1016\/j.jval.2026.07.002_bib32","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.jval.2026.07.002_bib33","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s41669-023-00423-0","article-title":"Health state utility values in early-stage non-small cell lung cancer: a systematic literature review","volume":"7","author":"Jovanoski","year":"2023","journal-title":"Pharmacoecon Open"},{"issue":"8","key":"10.1016\/j.jval.2026.07.002_bib34","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1097\/JTO.0b013e318299243b","article-title":"Health-related quality of life and utility in patients with advanced non-small-cell lung cancer: a prospective cross-sectional patient survey in a real-world setting","volume":"8","author":"Chouaid","year":"2013","journal-title":"J Thorac Oncol"},{"issue":"10","key":"10.1016\/j.jval.2026.07.002_bib35","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1136\/thx.2010.136390","article-title":"Health-related quality of life in patients surviving non-small cell lung cancer","volume":"65","author":"Grutters","year":"2010","journal-title":"Thorax"},{"issue":"8","key":"10.1016\/j.jval.2026.07.002_bib36","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1007\/s11136-020-02488-4","article-title":"Challenges and lessons learned from using anchoring vignettes to explore quality of life response behavior","volume":"29","author":"Topp","year":"2020","journal-title":"Qual Life Res"},{"issue":"1","key":"10.1016\/j.jval.2026.07.002_bib37","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/14737167.2023.2144837","article-title":"Cost-effectiveness of anlotinib vs pembrolizumab and nivolumab as third-line treatment in recurrent small cell lung cancer in China","volume":"23","author":"Fei","year":"2023","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.jval.2026.07.002_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1131219","article-title":"Toripalimab plus chemotherapy vs chemotherapy in patients with advanced non-small-cell lung cancer: a cost-effectiveness analysis","volume":"14","author":"Huo","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jval.2026.07.002_bib39","article-title":"Sugemalimab plus chemotherapy vs chemotherapy for metastatic non-small-cell lung cancer: a cost-effectiveness analysis","volume":"11","author":"Liang","year":"2023","journal-title":"Front Public Health"},{"key":"10.1016\/j.jval.2026.07.002_bib40","article-title":"Economic evaluation of toripalimab combined with chemotherapy in the treatment of non-small cell lung cancer","volume":"11","author":"Wang","year":"2023","journal-title":"Front Public Health"},{"key":"10.1016\/j.jval.2026.07.002_bib41","article-title":"Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: a sequential model","volume":"11","author":"Zhao","year":"2023","journal-title":"Front Public Health"},{"issue":"6","key":"10.1016\/j.jval.2026.07.002_bib42","doi-asserted-by":"crossref","first-page":"E34","DOI":"10.1177\/0272989X11421529","article-title":"Systematic review and empirical comparison of contemporaneous EQ-5D and SF-6D group mean scores","volume":"31","author":"Whitehurst","year":"2011","journal-title":"Med Decis Mak"},{"issue":"3","key":"10.1016\/j.jval.2026.07.002_bib43","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/ene.13836","article-title":"EQ-5D-5L and SF-6D health utility index scores in patients with myasthenia gravis","volume":"26","author":"Barnett","year":"2019","journal-title":"Eur J Neurol"},{"issue":"1","key":"10.1016\/j.jval.2026.07.002_bib44","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s10198-023-01566-x","article-title":"Comparative performance and mapping algorithms between EQ-5D-5L and SF-6Dv2 among the Chinese general population","volume":"25","author":"Xie","year":"2024","journal-title":"Eur J Health Econ"},{"issue":"5","key":"10.1016\/j.jval.2026.07.002_bib45","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s40273-024-01360-4","article-title":"Population norms for the EQ-5D-5L, PROPr and SF-6D in Hungary","volume":"42","author":"Nikl","year":"2024","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"10.1016\/j.jval.2026.07.002_bib46","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s10198-022-01523-0","article-title":"Comparison of EQ-5D-5L and EORTC QLU-C10D utilities in gastric cancer patients","volume":"24","author":"Pan","year":"2023","journal-title":"Eur J Health Econ"},{"issue":"7","key":"10.1016\/j.jval.2026.07.002_bib47","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1007\/s00198-011-1770-3","article-title":"SF-6D and EQ-5D result in widely divergent incremental cost-effectiveness ratios in a clinical trial of older women: implications for health policy decisions","volume":"23","author":"Davis","year":"2012","journal-title":"Osteoporos Int"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301526025647?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301526025647?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T19:59:06Z","timestamp":1789415946000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301526025647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":44,"alternative-id":["S1098301526025647"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2026.07.002","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health-Related Quality of Life and Utility Values in Chinese Patients With Non-Small Cell Lung Cancer: A Multicenter Study","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2026.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}